“Biotron's BIT225 may serve as the key in the fight against inaccessible pockets of HIV. Biotron's phase 1b/2a clinical trials results indicated that in combination with cART, BIT225 successfully reduced HIV RNA, inhibited replication in myeloid -lineage cells, and crossed the blood-brain barrier to reach latent viral reservoirs. With the promise of reaching previously untouched sites of disease, BIT225 may work in combination with today's approved cART medicines to collectively annihilate HIV once and for all. With preparations being made for a phase 2b study, it has yet to be seen just how safe and effective it will be in treating large cohorts of HIV-positive patients.”
“The results reported here are preliminary, and ongoing analysis of the BIT225-010 study, as well as its companion study, BIT225-011 in HIV-1 chronically infected individuals, will be reported when complete.”
exciting times ahead, remember this is being compared with big pharms like Gilead Sciences ( GS-CA1) & GlaxoSmithKline (GSK3640254)
“Biotron's BIT225 may serve as the key in the fight against...
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
